Dr Reddys Laboratories
Dr. Reddy's Laboratories, a prominent player in the global pharmaceutical industry, is headquartered in Hyderabad, India. Founded in 1984, the company has established a strong presence in key operational regions, including North America, Europe, and emerging markets. Specialising in generic medications, active pharmaceutical ingredients (APIs), and proprietary products, Dr. Reddy's is renowned for its commitment to quality and innovation. With a diverse portfolio that includes over 190 generic medicines and a robust pipeline of new drug applications, the company has achieved significant milestones, such as its successful entry into the biosimilars market. Dr. Reddy's Laboratories is recognised for its strategic partnerships and has garnered a solid market position, making it a trusted name in healthcare.
DitchCarbon Score
How does Dr Reddys Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dr Reddys Laboratories's score of 71 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Dr Reddys Laboratories's reported carbon emissions
In 2023, Dr Reddy's Laboratories reported total greenhouse gas emissions of approximately 1.27 million tonnes CO2e, comprising 214,257 tonnes (Scope 1), 137,627 tonnes (Scope 2), and about 921,055 tonnes (Scope 3). The company has set ambitious climate commitments, aiming for a 55% reduction in overall carbon emissions by 2030, using 2018 as the base year. Additionally, Dr Reddy's has committed to reducing Scope 1 and 2 emissions by 50.2% per million USD revenue by FY2031, which translates to a 25% absolute reduction from the FY2021 baseline. For Scope 3 emissions, the target is a 12.3% reduction within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) and are designed to support global efforts to limit temperature rise to well below 2°C.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 349,108,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 195,287,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 345,407,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dr Reddys Laboratories is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
